Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study

Abstract

Introduction: MATCH was a randomized, double-blind, placebo-controlled study enrolling Japanese and Korean men aged C 40 years who still had overactive bladder (OAB) symptoms while receiving tamsulosin. After a 4-week single-blind screening period in which patients received placebo and tamsulosin, patients were randomized to mirabegron 50 mg ? tamsulosin or placebo ? tamsulosin for 12 weeks (n = 568). This post hoc analysis investigated the proportion of treatment responders for each treatment group and for subgroups stratified by age based on voiding diaries and patient-reported outcomes (PROs). Methods: Responders were defined as those achieving normalization or clinically meaningful improvements in efficacy, or clinically important differences in PROs [C 10-point improvement in OAB questionnaire (OAB-q) symptom bother or total health-related quality of life (HRQoL) subscales at end of treatment (EoT; minimally important difference [MID]) or OAB symptom score (OABSS) total score decreased by C 3 points at EoT [minimally clinically important change (MCIC)]]. Results: At EoT, micturition frequency normalization was achieved by 30.7% of tamsulosin ? mirabegron patients and 18.6% of tamsulosin ? placebo patients. Normalization of urgency and incontinence was 19.1% and